Naproxen is named as an intervention in 2 current clinical trials in our Canada and South Korea registers. None are recruiting at the moment. The most common phase is Phase 3. The sponsor with the most trials is Ottawa Hospital Research Institute (1). The most-studied condition is Cellulitis. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Naproxen Versus Placebo as Adjunct Treatment of Cellulitis
NCT07665476 · ClinicalTrials.gov ↗ · Cellulitis, Skin Disease, Infectious, Infection
|
Phase 3 | Not yet open | Ottawa Hospital Research Institute | Canada |
|
A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers
NCT07277712 · ClinicalTrials.gov ↗ · Healthy Volunteer
|
Phase 1 | Not yet open | HK inno.N Corporation | South Korea |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Naproxen. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
4 single-substance products containing Naproxen on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| Ottawa Hospital Research Institute | 1 |
| HK inno.N Corporation | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in South Korea | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our Canada and South Korea registers name Naproxen as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Ottawa Hospital Research Institute (1) and HK inno.N Corporation (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 4 single-substance products containing Naproxen, for example Naprosyn EC 250mg Gastro-resistant Tablets (Atnahs Pharma Netherlands B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 3 entries for Naproxen: 3 German notices. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Naproxen works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Naproxen works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Naproxen (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.